Soraia Lobo-Martins

5PUBLICATIONS
47CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 10, 2026
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

|Feb 03, 2026
Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer.

Soraia Lobo-Martins, Stephen J Luen, Martine Piccart

|Jan 10, 2026
Age and Clinical Outcomes of Immune Checkpoint Inhibitor Toxicities in Portugal: A Decade of Pharmacovigilance.

Tiago Pina-Cabral, José Pereira, João Paulo-Fernandes

|Aug 28, 2024
Effect of Cyclin-Dependent Kinase 4/6 Inhibitors on Circulating Cells in Patients with Metastatic Breast Cancer.

Soraia Lobo-Martins, Patrícia Corredeira, Ana Cavaco

|Jul 30, 2020
Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases.

Soraia Lobo-Martins, Arlindo R Ferreira, André Mansinho

Pageof 1

Frequent Collaborators

2 joint publications

Sandra Casimiro

1 joint publications

Arlindo R Ferreira

1 joint publications

André Mansinho

1 joint publications

Kim Leitzel